Although Exubera is turning out to be a flop, you can’t say it’s not good for something. Turns out it’s good for disciplining deadbeat husbands, fighting off dogs while jogging, and rolling dough.

According to analysts, Pfizer was slow to market with Exubera, initially assigning it to a sales team that was not prepared to [...]

[Read more →]

Glaxo pulled a rabbit out of the hat in its earnings report today with a little misdirection. Per MarketWatch:
GlaxoSmithKline on Wednesday took some of the attention away from disappointing sales of diabetes drugs by announcing it was lifting its stock buyback authorization to 12 billion pounds ($24.7 billion).
Experts expected to see Glaxo report a [...]

[Read more →]

It appears someone finally decided to take a look at the effectiveness and benefits of older diabetes drugs (such as metformin) compared with newer, more expensive ones (such as Avandia). Dr. Shari Bolen of Johns Hopkins University studied various medical databases and found 216 relevant studies and two systematic reviews. According to Reuters:
Older [...]

[Read more →]